Search
vTv Therapeutics Inc
VTVTAdd to Watchlist
35.400USD
+0.350+1.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
139.44MMarket Cap
LossP/E TTM
More Details of vTv Therapeutics Inc Company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
vTv Therapeutics Inc Info
Ticker SymbolVTVT
Company namevTv Therapeutics Inc
IPO dateJul 30, 2015
CEOSekhri (Paul Jai)
Number of employees23
Security typeOrdinary Share
Fiscal year-endJul 30
Address3980 Premier Dr
CityHIGH POINT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27265
Phone13368410300
Websitehttps://vtvtherapeutics.com/
Ticker SymbolVTVT
IPO dateJul 30, 2015
CEOSekhri (Paul Jai)
Company Executives of vTv Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of vTv Therapeutics Inc?
The top five shareholders of vTv Therapeutics Inc are: Dr. Srinivas Akkaraju, M.D., Ph.D.
How many institutions hold shares of vTv Therapeutics Inc (VTVT)?
As of 2026Q1, 47 institutions hold shares of vTv Therapeutics Inc, with a combined market value of approximately 1.41M, accounting for 35.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 186915.00.